Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
David Braun, MD, PhD, discusses how biomarkers are evolving for the treatment of renal cell carcinoma.
Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study in advanced renal cell carcinoma (RCC).
Protein glycosylation may predict response to NIVO+CABO vs SUN in aRCC, with glycopeptides and complement proteins linked to progression-free survival and outcomes.
The SUNNIFORECAST trial (LBA75), presented by Dr. Lothar Bergmann from Germany on Friday, September 13, at the European Society for Medical Oncology Congress...
Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual ...
This case report describes a rare instance of extrarenal clear cell renal cell carcinoma (ccRCC) in a 48-year-old woman who presented with a loss of consciou...
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Medical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Medical experts will discuss the updated NCCN guidelines favoring ipilimumab + plus nivolumab for patients with favorable risk, including the data supporting this change and its the potential impact on the disease landscape.
“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.